Literature DB >> 10362853

Insulin sensitivity, clearance and release in kininogen-deficient rats.

J Damas1, V Bourdon, P J Lefebvre.   

Abstract

Insulin sensitivity of kininogen-deficient rats was compared with that of normal rats using euglycaemic hyperinsulinaemic glucose clamping. Anaesthetized animals were infused with 2-50 mU kg-1 min-1 of insulin and the glucose infusion rates needed to maintain euglycaemia were determined. Maximum glucose uptake, insulin sensitivity index and insulin clearance were reduced in kininogen-deficient rats. Captopril increased the amount of glucose needed to maintain euglycaemia during infusion of 2 and 10 mU kg-1 min-1 of insulin in normal rats, but had no effect in kininogen-deficient rats. Anaesthetized rats of both strains were given an intraperitoneal injection of glucose and the evolution of blood glucose was followed for 120 min. The peak increase was higher in kininogen-deficient rats. Similar larger increases in blood glucose were observed after glucose injection in normal rats previously treated with HOE 140, a bradykinin B2 receptor antagonist. After glucose injection, plasma insulin increased in both groups of rats but reached lower levels in kininogen-deficient animals. These results suggest that bradykinin is involved not only in the clearance of glucose and insulin by the tissues during insulin infusion but also that bradykinin can affect the release of insulin after a glucose load.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362853     DOI: 10.1111/j.1469-445x.1999.01812.x

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  9 in total

1.  Plasma Protein Biomarkers Correlated with the Development of Diet-Induced Type 2 Diabetes in Mice.

Authors:  Shigeru Okada; Edward O List; Sudha Sankaran; John J Kopchick
Journal:  Clin Proteomics       Date:  2010-06-01       Impact factor: 3.988

2.  Postexercise skeletal muscle glucose transport is normal in kininogen-deficient rats.

Authors:  George G Schweitzer; Gregory D Cartee
Journal:  Med Sci Sports Exerc       Date:  2011-07       Impact factor: 5.411

3.  Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat.

Authors:  V Arbin; N Claperon; M C Fournié-Zaluski; B P Roques; J Peyroux
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

4.  The renin angiotensin system and the metabolic syndrome.

Authors:  Chih-Hong Wang; Feng Li; Nobuyuki Takahashi
Journal:  Open Hypertens J       Date:  2010

5.  The B2 receptor of bradykinin is not essential for the post-exercise increase in glucose uptake by insulin-stimulated mouse skeletal muscle.

Authors:  G G Schweitzer; C M Castorena; T Hamada; K Funai; E B Arias; G D Cartee
Journal:  Physiol Res       Date:  2011-03-14       Impact factor: 1.881

6.  Changes in blood glucose and plasma insulin levels induced by bradykinin in anaesthetized rats.

Authors:  J Damas; C Hallet; P J Lefebvre
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

7.  Characterization of the Skeletal Muscle Proteome in Undernourished Old Rats.

Authors:  Caroline Barbé; Jérôme Salles; Christophe Chambon; Christophe Giraudet; Phelipe Sanchez; Véronique Patrac; Philippe Denis; Yves Boirie; Stéphane Walrand; Marine Gueugneau
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 8.  Evidence and evidence gaps of medical treatment of non-tumorous diseases of the head and neck.

Authors:  Murat Bas
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2016-12-15

9.  Preclinical characterization of recombinant human tissue kallikrein-1 as a novel treatment for type 2 diabetes mellitus.

Authors:  Tadeusz Kolodka; Matthew L Charles; Arvind Raghavan; Ilian A Radichev; Christina Amatya; Jacob Ellefson; Alexei Y Savinov; Abhijeet Nag; Mark S Williams; Mark S Robbins
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.